First class teams
PHARMNOVO IS A BIOPHARMA COMPANY performing research and development in collaboration with internationally leading academic and pharmaceutical scientists in their fields related to pain and pain therapy.
Our People » Our Network
PHARMNOVO IS A BIOPHARMA COMPANY performing research and development in collaboration with internationally leading academic and pharmaceutical scientists in their fields related to pain and pain therapy.
THE PRE-CLINICAL PHASE of the PN6047 development project is fundamentally complete and planning is now in train for regulatory toxicology testing and first in man clinical trials. The regulatory toxicology programme is being designed in collaboration with selected experts who will advise and manage the conduct and analysis of the animal testing.
Clinical input into the remaining phases of the project is clearly necessary and PharmNovo has put together a first class clinical team. The team includes; Andrew Rice, Professor of Pain Research, Imperial College, London; (link), Dr Roger Knaggs, Associate Professor in Pharmacy Practice, University of Nottingham (link), Chair of the UK Clinical Pharmacy Association pain management group) and Dr Peder Andersson, Chief Executive Officer, Biosergen.
Together with Board member Dr Anthony Ford, the team has huge experience of overseeing clinical testing of new drugs, interaction with regulatory bodies and progression to the market.
In August 2022, PharmNovo initiated the First-In-Human, (FIH), clinical study for the company’s drug candidate PN6047, aimed at evaluating its safety and tolerability. By August 2023, the study was completed, involving 104 subjects across 13 cohorts, which included both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts. Each cohort consisted of 8 subjects, with 6 receiving active treatment and 2 receiving placebo.
Read morePharmNovo participated at the BioStock Investor Meeting in Stockholm on September 20. Our CEO presented the development and phase I clinical study of our drug candidate PN6047, which is in its final phase.
Read moreWe are delighted to share promising preclinical results for our innovative drug candidate PN6047, further confirming its safety profile. PN6047 is designed to provide relief from neuropathic pain, and these findings reinforce our commitment to safe and effective pain management as we prepare for Phase II trials in 2024.
Read more